Edition:
United States

Accuray Inc (ARAY.OQ)

ARAY.OQ on NASDAQ Stock Exchange Global Select Market

4.95USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$4.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
150,593
52-wk High
$7.18
52-wk Low
$4.55

ARAY.OQ

Chart for ARAY.OQ

About

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife... (more)

Overall

Beta: 1.76
Market Cap(Mil.): $432.98
Shares Outstanding(Mil.): 81.69
Dividend: --
Yield (%): --

Financials

  ARAY.OQ Industry Sector
P/E (TTM): -- 46.95 29.87
EPS (TTM): -0.28 -- --
ROI: -9.98 7.26 14.95
ROE: -38.13 9.04 16.29

BRIEF-Accuray entered into an amendment to financing agreement

* Accuray - On November 4, entered into an amendment to financing agreement dated as of January 11, 2016 - SEC filing

Nov 04 2016

BRIEF-Accuray Q1 loss per share $0.12

* Accuray reports financial results for first quarter and affirms full year fiscal 2017 guidance

Oct 27 2016

BRIEF-Accuray announces results from multi-institutional study

* Data from prospective, 21 center study showed 97 percent cancer patients had cancer control 5 years after SBRT; treatment extremely well-tolerated Source text for Eikon: Further company coverage:

Sep 27 2016

BRIEF-Emad Rizk of Accuray tendered his resignation from the board

* On september 16, 2016, Emad Rizk tendered his resignation from the board of directors - SEC filing

Sep 20 2016

BRIEF-Accuray reports Q4 loss per share $0.09

* Accuray reports fourth quarter and fiscal 2016 financial results

Aug 17 2016

BRIEF-Accuray CE marks its radixact system

* CE marked its radixact treatment delivery system, Accuray precision treatment planning system and IDMS data management system

Aug 09 2016

BRIEF-Accuray retires remaining 3.75 percent convertible debt

* Says 2016 notes were settled on August 1 for $37.3 million, which included $36.6 million in principal and $0.7 million in accrued interest

Aug 02 2016

BRIEF-Accuray receives 510(K) FDA clearance for image-guided radiation therapy

* Accuray receives 510(k) FDA clearance for the Radixact image-guided radiation therapy platform and integrated software

Jun 27 2016

Earnings vs. Estimates